参考文献

［1］Marian AJ, Tan Y, Li L, et al. Hypertrophy regression with n-acetylcysteine in hypertrophic cardiomyopathy (HALTHCM) novelty and significance. Circ Res, 2018；122(8): 1109-1118.

［2］Kawas RF, Anderson RL, Ingle SRB, et al. A smallmolecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem 2017; 292(40): 16571-16577.(https://www.daowen.com)

［3］Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2020(9), 396, 759-769.

（袁华苑　李建美）